LENZ Therapeutics, Inc. (LENZ)
AI-powered earnings prediction for LENZ Therapeutics, Inc. (LENZ).
8.53
+1.55%
USD, about 18 hours ago
Company Overview
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Sector
Healthcare
Industry
Biotechnology
Website
www.lenz-tx.comPhone
858 925 7000
Headquarters
201 Lomas Santa Fe Drive
Solana Beach, CA, 92075
United States
Full-Time Employees
152
Key Metrics
Forward P/E
-3.21
Price to Book
0.93
Beta
1.76
Profit Margin
0.00%
Gross Margin
97.81%
Return on Equity
-33.63%
Return on Assets
-21.86%
Earnings Growth
N/A
Revenue Growth
N/A
Financial Health
Total Cash
$292.35M
Total Debt
$815000.00
Debt to Equity
0.29
Current Ratio
14.23
Free Cash Flow
$-40249248.00
Operating Cash Flow
$-69170000.00
Analyst Recommendations
Target Price (Mean)
$41.14
Target High
$60.00
Target Low
$20.00
Recommendation
strong_buy
Analyst Coverage
7 Analysts